atazanavir / Generic mfg. - LARVOL DELTA

Development of a PCR-based technique for genotyping UGT1A1 gene and distribution of rs3064744 alleles in the Russian population. (PubMed, Front Genet) - "Accurate determination of tandem thymine-adenine (TA) repeat numbers in the UGT1A1 promoter region (rs3064744) is essential for diagnosing Gilbert's syndrome and personalizing therapy with toxic agents like irinotecan and atazanavir. Combining LNA-modified aPCR-MCA with a comparative 1D-CNN model successfully circumvents thermodynamic limitations and eliminates human operator bias. This integrated system offers an accessible, high-throughput, and clinically valid solution for routine UGT1A1 pharmacogenetic testing."

Journal • Hepatology • UGT1A1

Breastmilk transfer and infant exposure to atazanavir/ritonavir in breastfeeding women with HIV: results from IMPAACT 2026. (PubMed, Front Reprod Health) - "No maternal adverse events occurred; three infants experienced unrelated grade 2 events. In this cohort, ATV and RTV were detectable in maternal plasma and breastmilk but not in infant plasma, with low RID estimates and a favorable safety profile."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Model-based clinical utility of pharmacogenetic testing and its potential population impact on the use of essential medicines in Zimbabwe. (PubMed, Front Pharmacol) - "Lower NNG values were observed for UGT1A1-atazanavir (5), UGT1A1-irinotecan (9), CYP2B6-efavirenz (26), and CYP2C9-phenytoin (25), whereas 61% of gene-drug pairs had NNG values > 1,000 compared with 47% in the Dutch population. Many essential medicines in Zimbabwe have actionable pharmacogenomic biomarkers, but gaps in local genomic guidance remain. Strengthening local evidence generation and PGx implementation is essential."

Biomarker • Journal • CYP2C9 • UGT1A1

Deep learning-based prediction of drug-target interactions between antiviral drugs and SARS-CoV-2 proteins using an image-based representation approach. (PubMed, Comput Biol Chem) - "Results consistently identified five antivirals - MK-5172 (Grazoprevir), Simeprevir, Lopinavir, Etravirine, and Atazanavir - as top-ranked candidates across all targets. Comparative analysis with the MT-DTI model demonstrated competitive and, in several cases, superior ranking performance despite a simpler architecture. Importantly, these predictions are supported by independent experimental and clinical evidence, highlighting the potential of image-based representations as a computationally efficient and biologically meaningful approach for drug-target interaction prediction and drug repurposing."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Association between integrase inhibitors (INSTIs) and tenofovir alafenamide (TAF) and moderate chronic kidney disease (CKD) in the RESPOND HIV cohort collaboration (AIDS 2026) - "We assessed CKD risks associated with (1) INSTIs vs non-nucleoside reverse transcriptase inhibitors (NNRTIs) and (2) TAF vs lamivudine (3TC), with both comparators considered kidney neutral...To account for artefactual creatinine increases when starting INSTIs and rilpivirine, baseline was defined as 6 months after starting treatment... After accounting for differences in participant characteristics, there was no increased CKD risk associated with INSTIs or TAF, although confidence intervals were relatively wide."

Cardiovascular • Chronic Kidney Disease • Diabetes • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • CD4

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (clinicaltrialsregister.eu) - P4 | N=290 | Sponsor: Gilead Sciences, Inc.

New P4 trial • Human Immunodeficiency Virus • Infectious Disease • Pediatrics

Affordability of antiretrovirals: have productive development partnerships for local production and technology transfer contributed to the sustainability of Brazil’s universal access policy? (AIDS 2026) - " Ten active PDPs (4 in Phase III; 6 in Phase IV) for 7 ARVs (atazanavir, darunavir, dolutegravir, emtricitabine/lamivudine, ritonavir, tenofovir, and tenofovir/lamivudine) were identified, involving 12 laboratories (5 public, 5 private national and 2 international). While local production is vital for health sovereignty, PDPs did not consistently contribute to ARV affordability from 2015-2025. Competition appears to remain a key driver for price reduction. Recent policy updates might correct existing distortions to ensure greater affordability gains."

Human Immunodeficiency Virus • Infectious Disease

Risk factors for antiretroviral treatment interruption in Brazil: a national retrospective cohort study (2023-2024) (AIDS 2026) - "Factors associated with a higher risk of ATI were female sex (aRR=1.24; 95%CI 1.22–1.26), age 18–24 years (aRR=2.21; 95%CI 2.14–2.29), age 25–39 years (aRR=1.53; 95%CI 1.50–1.56), non-White/Asian ethnicity (aRR=1.33; 95%CI 1.30–1.35), <1 year of treatment (aRR=1.27; 95%CI 1.23–1.32), 1–9 years of treatment (aRR=1.13; 95%CI 1.10–1.15), regimens containing tenofovir disoproxil (aRR=1.70; 95%CI 1.65–1.75), and regimens containing atazanavir (aRR=1.66; 95%CI 1.61–1.72)... In Brazil, the risk of treatment interruption remains associated with sociodemographic factors, disproportionately affecting women, younger adults, and non-White/Asian individuals, and shows a clear inverse relationship with total time on treatment. Antiretroviral drugs used appear to have a greater impact on adherence among adults than the daily pill burden. These findings highlight priority groups for targeted interventions aimed at reducing treatment interruption and improving long-term retention in..."

Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV. (PubMed, Antimicrob Agents Chemother) - P=N/A | "We investigated the effect of weight, age, atazanavir formulation, ritonavir dose, and NRTI backbone (tenofovir alafenamide [TAF]-emtricitabine, abacavir-lamivudine, or zidovudine-lamivudine). When simulating pharmacokinetics during rifampicin co-treatment, twice-daily atazanavir/r is expected to restore exposures to levels comparable to once-daily dosing without rifampicin. These findings provide a framework for future clinical evaluation in children with HIV and tuberculosis."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Unveiling the role of UGT enzymes in chemoresistance: a path to enhanced cancer pharmacotherapy. (PubMed, Cancer Drug Resist) - "Here we present new HepG2 models transduced with UGT1A1 or UGT2B7 that provide mechanistic insights into the potential role of UGTs in resistance to SN-38, etoposide, and epirubicin... The comparative ATP viability assays and verification studies using the UGT inhibitors atazanavir and diclofenac confirmed that both UGT enzymes significantly reduced the tested drugs' pharmacodynamic activity. Drug combination experiments then showed that UGT1A1 activity can be synergistically targeted by nilotinib and regorafenib via a new dual-activity modulation approach. Finally, the role of UGT1A1 in resistance to SN-38 was confirmed in a complex model based on primary upcyte hepatocytes. After in vivo confirmation, our findings could potentially be translated into effective and safe combination regimens for oncology patients."

Journal • Oncology • UGT1A1

Brief communication: clinical jaundice is associated with poor adherence to boosted atazanavir among adults in an HIV clinic in Kampala, Uganda. (PubMed, AIDS Res Ther) - "Clinical jaundice is common among patients on ATV/r in Uganda and is associated with poor ART adherence. Strengthening pre-ATV/r (pre-switch) counselling and exploring safer regimen alternatives are required to improve outcomes."

Journal • Human Immunodeficiency Virus • Infectious Disease

Prescription of colchicine and NSAIDs for acute gout flares in severe chronic kidney disease and colchicine in major drug–drug interactions: evidence from an electronic health-record based gout register (EULAR 2026) - "Strong inhibitors included atazanavir, clarithromycin, cobicistat, darunavir, fluconazole, ketoconazole, lopinavir, ritonavir, nirmatrelvir–ritonavir, voriconazole, and ciclosporin. Moderate to weak inhibitors included erythromycin, verapamil, amiodarone, diltiazem, and dronedarone...Conclusions Colchicine was frequently prescribed for acute gout flares in patients with severe chronic kidney disease despite society guideline recommendations, although co-prescription with strong CYP3A4 or P-glycoprotein inhibitors was uncommon. These findings suggest partial adherence to recommendations and warrant further evaluation of colchicine safety in patients with severe chronic kidney disease."

Chronic Kidney Disease • Gout • Inflammatory Arthritis • Nephrology • Renal Disease • Rheumatology • CYP3A4

Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb-Drug Interaction Investigation. (PubMed, Biopharm Drug Dispos) - "No relevant changes were observed in clearance, half-life, or mean residence time for either drug. These findings indicate that repeated Echinacea administration does not result in a pharmacokinetically relevant interaction with favipiravir or atazanavir under the investigated conditions."

Journal • PK/PD data

Risk of Developing Low-Level Viral Rebound Among People With HIV Receiving 2- or 3-Drug Regimens: A Case-Control Study Nested in the ICONA Cohort. (PubMed, Open Forum Infect Dis) - "The cumulative incidence of LLVR after virological suppression was estimated using Kaplan-Meier methods, and conditional logistic regression models were used to evaluate the association between the current antiretroviral therapy regimen (2DR [dolutegravir/lamivudine, dolutegravir/rilpivirine, dolutegravir/doravirine, or cabotegravir/rilpivirine] vs 3DR [dolutegravir, bictegravir, rilpivirine, doravirine, boosted darunavir, or boosted atazanavir-based with a backbone of tenofovir and lamivudine or emtricitabine]) and LLVR risk. After adjusting for confounding, evidence for an association with current regimen was inconclusive (adjusted odds ratio, 0.86 [95% CI, .57-1.29]). Despite the wide range of plausibility, we can exclude a risk of LLVR higher than 29% when using 2DR versus 3DR regimens."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Opsoclonus myoclonus syndrome in an HIV patient, following plasmodium falciparum infection. (PubMed, Neurocase) - "This is a 47-year-old woman, known to be HIV-positive, for the past 6 years, and on highly active antiretroviral therapy (HAART) with Tenofovir-Lamivudine-Atazanavir, to which she is strictly compliant...Initial management consisted of high doses of intravenous (IV) methylprednisolone which resulted in partial improvement of the symptoms. The subsequent addition of rituximab led to complete resolution of the symptoms and the restoration of functional autonomy. This case suggests a possible relationship between malaria and OMS in the context of HIV infection and highlights the potential benefit of an IV corticosteroid and rituximab combination therapy as a substitute for IV immunoglobulins in resource-limited settings."

Journal • Ataxia • CNS Disorders • Human Immunodeficiency Virus • Infectious Disease • Malaria • Movement Disorders • Oncology • Sleep Disorder

Pre-treatment drug resistance surveillance among ART- Naive HIV-1 patients in Tunisia. (PubMed, Virusdisease) - "K103N is the most involved SDRM-inducing resistance to NNRTIs (efavirenz, nevirapine, and rilpivirine). In the PR gene, resistance was found in four samples on 46 and 85 codons, affecting the sensitivity for Atazanavir and Lopinavir drugs. The subtying revealed the predominance of the CRF02_AG, followed by the subtype B. This study provides the first baseline information for pre-treatment drug resistance surveillance of HIV-1 variants in Tunisia, which may impede patient management."

Journal • Human Immunodeficiency Virus • Infectious Disease

Study of the possibility of isolating atazanavir from biological fluids for the purpose of chemical-toxicological analysis (PubMed, Sud Med Ekspert) - "The article presents the results of developing optimal conditions for extracting atazanavir using liquid-liquid extraction from physiological fluids (urine, saliva, and blood plasma), as well as identifying and quantifying this substance in extracts using thin-layer chromatography, UV spectrophotometry, and high-performance liquid chromatography."

Journal

UGT1A1 Fragment Analysis: Genotyping the (TA)n Variable Repeat Polymorphism for Clinical Applications. (PubMed, J Clin Lab Anal) - "Clinical implementation as a supplemental assay to other pharmacogenomics offerings resulted in a correction rate of the loci within patient samples of 7.8%, with 2.77% caused by miscalling UGT1A1*37 variant."

Journal • UGT1A1

Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "Model simulations linked nilotinib-induced hyperbilirubinemia to UGT1A1 mutations, and simulations were used to assess the risk of hyperbilirubinemia associated with varying doses of nelfinavir, atazanavir, and TAK-875, based on their off-target effects on transporters. Results demonstrated that uncertainty in free drug tissue concentration may be crucial in hyperbilirubinemia, especially for highly protein-bound drugs. This approach may help assess hyperbilirubinemia risk using a drug's inhibitory in vitro data coupled with patient pharmacogenetic data for OATP1B1, UGT1A1, and MRP2 mutations."

Journal • Genetic Disorders • ABCC3 • UGT1A1

Metabolic dysfunction-associated steatotic liver disease linked to antiretroviral exposure in cohort of people with HIV. (PubMed, AIDS) - "Our findings suggest that commonly used antiretrovirals may contribute to the development of MASLD. Prospective studies examining the possible causal effects of these therapies on MASLD development and progression are warranted."

Journal • Diabetes • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Forecasting drug resistant HIV protease evolution. (PubMed, PLoS Comput Biol) - "Our analysis shows that the dual therapy of Atazanavir (ATV) and Ritonavir (RTV) is the multi-PI treatment regimen least likely to induce drug resistance. Interestingly, our results highlight the necessity of the amino-acid polymorphism of L63P by predicting that it is critical in developing resistance to Nelfinavir (NFV). The results validate that our framework effectively extracts and combines biological information from the distinct data sets of observed genotypes and drug resistance, while also tackling the challenge of sparsity of available sequence data compared to the large combinatorial complexity of protein evolution and changing functionality in dynamic environments."

Journal • Human Immunodeficiency Virus • Infectious Disease

A GPCR-G protein-β-arrestin megacomplex enabled by a versatile allosteric modulator. (PubMed, Cell) - "Remarkably, this compound, atazanavir, exhibits pan-receptor activation across multiple family A GPCRs, including GPR119, β1AR, and β2AR, demonstrating the broad applicability of this regulatory mechanism. This discovery uncovers a distinct mechanism of GPCR regulation, opening alternative avenues for the development of therapeutics targeting GPCRs."

Journal

Pure atazanavir kidney stone (PubMed, Rev Prat) - No abstract available

Journal • Nephrology • Renal Calculi

Development of a Physiologically Based Model of Bilirubin Metabolism in Health and Disease and Its Comparison With Real-World Data. (PubMed, CPT Pharmacometrics Syst Pharmacol) - "To also illustrate model behavior under targeted perturbations, we simulated administration of atazanavir in healthy individuals and patients with Gilbert syndrome to investigate its effect on bilirubin levels. Relative to baseline, unconjugated bilirubin maximum concentration (Cmax) increased by 34% in healthy individuals but by 67% in Gilbert syndrome. Overall, this study provides a conceptual and mechanistically informed framework for studying bilirubin homeostasis and the functional consequences of drug administration in health and disease."

Clinical • Journal • Real-world evidence • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Metabolic Disorders

Neurodevelopmental Risk in HIV-Exposed Uninfected Children: Call for Developmental Surveillance. (PubMed, J Pediatr Perinatol Child Health) - "This review underscores the need to integrate neurodevelopmental surveillance into pediatric HIV-exposed care, optimize anti-retroviral therapy regimens with consideration of fetal outcomes, and support caregiver- and community-based interventions that promote healthy development. Addressing the developmental needs of HEU children is critical to improving long-term outcomes and ensuring this growing population is not left behind."

Journal • Developmental Disorders • Human Immunodeficiency Virus • Infectious Disease • Pediatrics